Otamixaban (XRP0673) + Unfractionated Heparin
Phase 2Completed 0 views this week 0 watching💤 Quiet
Interest: 35/100
35
Development Stage
✓
Pre-clinical✓
Phase 13
Phase 24
Phase 35
ApprovedIndication / Disease
Angioplasty, Transluminal, Percutaneous Coronary
Conditions
Angioplasty, Transluminal, Percutaneous Coronary
Trial Timeline
Sep 1, 2004 → Oct 1, 2005
NCT ID
NCT00133731About Otamixaban (XRP0673) + Unfractionated Heparin
Otamixaban (XRP0673) + Unfractionated Heparin is a phase 2 stage product being developed by Sanofi for Angioplasty, Transluminal, Percutaneous Coronary. The current trial status is completed. This product is registered under clinical trial identifier NCT00133731. Target conditions include Angioplasty, Transluminal, Percutaneous Coronary.
What happened to similar drugs?
0 of 1 similar drugs in Angioplasty, Transluminal, Percutaneous Coronary were approved
Approved (0) Terminated (0) Active (1)
Hype Score Breakdown
Clinical
12
Activity
8
Company
15
Novelty
0
Community
0
Clinical Trials (1)
| NCT ID | Phase | Status |
|---|---|---|
| NCT00133731 | Phase 2 | Completed |
Competing Products
1 competing product in Angioplasty, Transluminal, Percutaneous Coronary
| Product | Company | Stage | Hype Score |
|---|---|---|---|
| fospropofol disodium | Eisai | Phase 3 | 40 |